Treatment with epigenetic modulators removes the repression and increases effector T cell tumor infiltration, slows down tumor progression, and improves the therapeutic efficacy of PD-L1 checkpoint blockade and adoptive T cell transfusion in tumor-bearing mice [25]. This evidence concerns the gene CD274 and neoplasm.